SMTL ID : 8tsa.1

Human PI3K p85alpha/p110alpha H1047R bound to compound 2

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.51 Å

Oligo State

hetero-1-1-mer

Ligands

1 x UIW: 5-(3-bromo-5-fluorobenzamido)-N-methyl-6-(2-methylanilino)pyridine-3-carboxamide(Non-covalent)

UIW.1: 17 residues within 4Å: Chain A: Q.819, L.822, T.823, I.920, L.921, G.922, I.923, F.947, L.948, K.951, F.1012, E.1022, L.1023, D.1028, I.1029, Y.1031, I.1032 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:E.1022, A:Y.1031, A:Y.1031, A:I.1032 Hydrogen bonds: A:L.921, A:G.922, A:K.951, A:D.1028 pi-Stacking: A:F.1012

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Varkaris, A. et al., Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3K alpha Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov (2024)

Release Date

2023-11-22

Peptides

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform: A
Phosphatidylinositol 3-kinase regulatory subunit alpha: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Phosphatidylinositol 3-kinase regulatory subunit alpha

Related Entries With Identical Sequence